Jon Soo Kim1, Hunmin Kim2, Byung Chan Lim3, Jong-Hee Chae3, Jieun Choi4, Ki Joong Kim3, Yong Seung Hwang3, Hee Hwang5. 1. Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea; Department of Pediatrics, Eulji University Hospital, Dae-jeon, Republic of Korea. 2. Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea. 3. Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul, Republic of Korea. 4. Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Pediatrics, SMG-SNU Boramae Hospital, Seoul, Republic of Korea. 5. Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea; Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: neuroandy@snubh.org.
Abstract
PURPOSE: To evaluate the efficacy and safety of lacosamide in pediatric patients with refractory focal epilepsy. METHODS: We reviewed retrospectively the medical records of children younger than 18 years of age treated at Seoul National University Bundang Hospital, in whom oral lacosamide was used as an adjunctive treatment for refractory focal epilepsy. Clinical information regarding the patients' epilepsy and the outcome of lacosamide treatment was gathered and analyzed. RESULTS: Twenty-one patients (16 boys, 5 girls) were included, with a median age of 13.9 (range, 1.2-17.9) years. The mean number of concomitant antiepileptic drugs was 3.0 (range, 1-6) and the mean duration of follow-up was 10.1 (range, 6.1-13.0) months. The mean maintenance dose of lacosamide was 5.4 (range, 1.4-9.8) mg/kg/day. Fourteen patients (67%) were responders; four of these were seizure free at the last follow-up. Seven patients (33%) were nonresponders: two of these presented with <50% seizure reduction and five showed no change in seizure frequency. Two patients (10%) discontinued oral lacosamide because of adverse events (aggressive behavior and depression). Mild transient treatment-related adverse events were observed in eight of the 21 patients (38%). CONCLUSIONS: Lacosamide represents a useful drug that is effective for a wide range of pediatric refractory focal epilepsy and is well tolerated.
PURPOSE: To evaluate the efficacy and safety of lacosamide in pediatric patients with refractory focal epilepsy. METHODS: We reviewed retrospectively the medical records of children younger than 18 years of age treated at Seoul National University Bundang Hospital, in whom oral lacosamide was used as an adjunctive treatment for refractory focal epilepsy. Clinical information regarding the patients' epilepsy and the outcome of lacosamide treatment was gathered and analyzed. RESULTS: Twenty-one patients (16 boys, 5 girls) were included, with a median age of 13.9 (range, 1.2-17.9) years. The mean number of concomitant antiepileptic drugs was 3.0 (range, 1-6) and the mean duration of follow-up was 10.1 (range, 6.1-13.0) months. The mean maintenance dose of lacosamide was 5.4 (range, 1.4-9.8) mg/kg/day. Fourteen patients (67%) were responders; four of these were seizure free at the last follow-up. Seven patients (33%) were nonresponders: two of these presented with <50% seizure reduction and five showed no change in seizure frequency. Two patients (10%) discontinued oral lacosamide because of adverse events (aggressive behavior and depression). Mild transient treatment-related adverse events were observed in eight of the 21 patients (38%). CONCLUSIONS:Lacosamide represents a useful drug that is effective for a wide range of pediatric refractory focal epilepsy and is well tolerated.
Authors: Martin J Brodie; Frank Besag; Alan B Ettinger; Marco Mula; Gabriella Gobbi; Stefano Comai; Albert P Aldenkamp; Bernhard J Steinhoff Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468
Authors: Viktor Farkas; Barbara Steinborn; J Robert Flamini; Ying Zhang; Nancy Yuen; Simon Borghs; Ali Bozorg; Tony Daniels; Paul Martin; Hannah C Carney; Svetlana Dimova; Ingrid E Scheffer Journal: Neurology Date: 2019-08-28 Impact factor: 9.910